Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 6, Pages 1335-1341Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1096352
Keywords
Diffuse large B-cell lymphoma; BCL2; MYC; relapse; refractory counts
Categories
Ask authors/readers for more resources
The clinical significance of concurrent expression of MYC and BCL2 protein, known as double-expressor lymphoma (DEL), among patients with relapsed or refractory aggressive B-cell lymphomas, remains unclear. A retrospective analysis was performed of 38 patients treated with a salvage treatment consisting of rituximab, ifosfamide, etoposide, cytarabine and dexamethasone followed by consolidative high-dose chemotherapies. A total of 17 cases (45%) were categorized as DEL using immunohistochemical assay with a cut-off value of positivity of 40% for MYC and 50% for BCL2, respectively. DEL was associated with a lower overall response rate (35% vs 71%, p=0.0481), worse 2-year progression-free survival (9% vs 67%, p=0.001) and overall survival (35% vs 71%, p=0.037). This analysis suggests that DEL is common among patients with relapsed/refractory aggressive B-cell lymphomas and that such patients require novel treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available